02590oam 2200589 a 450 991069065890332120040429091642.0(CKB)5470000002339723(OCoLC)41321493ocm41321493(OCoLC)995470000002339723(EXLCZ)99547000000233972319990507d1999 ua 0engurunu|||||txtrdacontentcrdamediacrrdacarrierRelative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostatic cancer[electronic resource][Rockville, Md.] :[U.S. Dept. of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research],[1999]Evidence report/technology assessment. Summary ;no. 4AHCPR publication ;no. 99-E011Title from title screen (viewed on Apr. 29, 2004)."January 1999.""The full evidence report from which this summary was taken was prepared by the Evaluation Technology Center, an AHCPR Evidence-based Practice Center of the Blue Cross and Blue Shield Association, Chicago, Illinois, under contract no. 290-97-0015."ProstateCancerHormone therapyAntiandrogensTherapeutic useAndrogen Antagoniststherapeutic useCost-Benefit AnalysisGonadotropin-Releasing Hormoneantagonists & inhibitorsOutcome Assessment, Health CareProstatic Neoplasmsdrug therapyRandomized Controlled Trials as TopicProstateCancerHormone therapy.AntiandrogensTherapeutic use.Androgen Antagoniststherapeutic use.Cost-Benefit Analysis.Gonadotropin-Releasing Hormoneantagonists & inhibitors.Outcome Assessment, Health Care.Prostatic Neoplasmsdrug therapy.Randomized Controlled Trials as Topic.United States.Agency for Health Care Policy and Research.Blue Cross and Blue Shield Association.Technology Evaluation Center.MMUMMUOCLOCLCQGPOBOOK9910690658903321Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostatic cancer3113110UNINA